Upgrades galore for NASDAQ:PIRS lately as analysts see great upside potential for the company. Most recently PIRS presented data from a phase 1 study on its new technology ANTICALIN which it is developing in collaboration with NYSE:AZN was released and commented on by the Chief development officer. "We are encouraged by the safety and tolerability of AZD1402/PRS-060 in this Phase 1a study, the first Anticalin protein dosed via inhalation,We look forward to completing and presenting the data from the multiple-ascending dose study, which will evaluate the FeNO-reducing potential of this drug candidate versus placebo, at an upcoming medical meeting." The stock is setting up in a bullish fashion having broken the downtrend resistance, backtested and now moves higher on good volume, while indicators all show significant strength. AVERAGE ANALYSTS RECOMMENDATION BUY AVERAGE ANALYSTS TARGET PRICE $7.33
COMPANY PROFILE Pieris Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of Anticalin-based drugs. Its pipeline includes immuno-oncology, respiratory, and anemia and other disease areas.